Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Mar
2
2019
The Farm Bill’s Impact on Hemp and CBD – and How Some States are Reacting Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
New Set Of Guidance From FDA Provides Clarity On Digital Health Policies, Machine Learning Sheppard, Mullin, Richter & Hampton LLP
May
11
2022
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
Jul
21
2022
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Mar
25
2020
Top 10 Questions Asked By Medical Group Clients In Response To COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Feb
22
2023
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs Sheppard, Mullin, Richter & Hampton LLP
Jun
19
2020
Not Today Corona: EEOC Prohibits Testing Employees for Antibodies Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2020
High Risk of Second Requests in the Cannabis Industry Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2023
On the Horizon: Broad Employment Protections for Marijuana Users in the District of Columbia Sheppard, Mullin, Richter & Hampton LLP
Aug
10
2020
“Buy American” in the Twilight Zone: Executive Order Strengthening the U.S. Public Health Industrial Base Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
FDA Issues First Untitled Letter of the Year to Xeris Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2023
Commercial Cannabis Permit Program and Overlay District Statutorily Exempt Under CEQA Guideline Section 15183 Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2023
Overview of Recent Anti-Corruption Enforcement Actions in the Pharmaceutical Industry in China Sheppard, Mullin, Richter & Hampton LLP
Jan
27
2021
CMS to the Rescue for MA and Part D Plans – Rate Announcement Includes Significant Increase in Plan Payments for 2022 Sheppard, Mullin, Richter & Hampton LLP
Mar
26
2021
Online Cannabis Marketplace Businessmen Convicted of Conspiracy to Commit Bank Fraud Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2011
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics Sheppard, Mullin, Richter & Hampton LLP
Nov
2
2018
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny Sheppard, Mullin, Richter & Hampton LLP
May
8
2019
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food Sheppard, Mullin, Richter & Hampton LLP
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Sep
28
2021
Nota Bene Episode 145: Tuna Sustainability: A Model Bigger than its Niche with ISSF President Susan Jackson [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2021
California Broadens Security and Breach Laws, Includes Genetic Data Sheppard, Mullin, Richter & Hampton LLP
Jan
4
2022
Cannabis Legislation Year-in-Review Sheppard, Mullin, Richter & Hampton LLP
Feb
11
2022
Federal Cannabis Reform – Is 2022 the Year? Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins